Onconova Therapeutics, Inc. to Present at Two Upcoming Healthcare Conferences
21 March 2017 - 11:30PM
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical stage
biopharmaceutical company focused on discovering and developing
novel products to treat cancer, today announced that Company
management will present an overview at the Sachs Fifth Annual
Cancer Bio Partnering and Investment Forum, and two posters at the
American Academy of Cancer Research (AACR) Annual Meeting.
Presentation Details: |
Sachs Fifth Annual Cancer Bio Partnering and Investment
Forum |
Date:
Tuesday, March 28th, 2017 |
Time: 11:55
am-12:15 pm |
Location: |
New York Academy of
Sciences |
|
Seven World Trade
Center, 250 Greenwich Street |
|
New York City |
Presenter:
Dr. Ramesh Kumar, President & CEO |
A recording
of the presentation will be available on Onconova’s website
approximately one week after the event and will be active for 90
days following the event. |
|
|
American Association of Cancer Research (AACR) Annual
Meeting |
Date: April
3rd, 2017 |
Time: 1:00
pm-5:00 pm |
Location:
Section 7 |
Walter E.
Washington Convention Center |
Washington,
D.C. |
Data in the
abstracts will be related to two pipeline compounds, both in
pre-clinical stages of development: |
• ON 123300 is a first in class dual inhibitor of CDK4/6 and
ARK5. |
|
• This compound is comparable to palbociclib (Pfizer’s
Ibrance®) which is approved for breast cancer and is considered a
blockbuster. |
|
• Unlike palbociclib, our third-generation molecule has the
potential to exhibit single agent activity and could be useful in
many indications beyond breast cancer, including hematological
cancers. |
|
• ON
123300 is covered by issued patents worldwide. |
|
• The presentation relates to efficacy in animal tumor model
showing differentiation from palbociclib and potent anticancer
activity. |
|
• This work was carried out by Onconova scientists and our
collaborators working at Long Island University. |
|
|
• ON 150030 is a dual inhibitor of Flt3 and Src kinases, both
validated targets for treatment of AML and other cancers |
|
• ON
150030 is a Type I inhibitor, differentiated from Type II
inhibitors like Quizartinib, which do not work against mutant
kinases. |
|
• Dual specificity allows for targeting both AML as well as
solid tumors. |
|
• This work was carried out by Onconova’s founding scientists
and colleagues, now working at Mount Sinai School of Medicine. |
|
|
About Onconova Therapeutics, Inc.Onconova
Therapeutics, Inc. is a Phase 3 stage biopharmaceutical
company focused on discovering and developing novel small molecule
drug candidates to treat cancer, with a primary focus on
Myelodysplastic Syndromes (MDS). Rigosertib, Onconova’s lead
candidate, is a proprietary phase 3 small molecule agent, which
blocks cellular signaling by targeting RAS effector pathways.
Using a proprietary chemistry platform, Onconova has created a
pipeline of targeted anti-cancer agents designed to work against
specific cellular pathways that are important in cancer cells,
while causing minimal damage to normal cells. Onconova
has three product candidates in clinical trials and several
active pre-clinical programs. Advanced clinical trials with
our lead compound, rigosertib, are aimed at unmet medical
needs of patients with MDS. For more information, please visit
http://www.onconova.com.
Forward Looking StatementsSome of the
statements in this release are forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, Section 21E of the Securities Exchange Act of 1934, as
amended, and the Private Securities Litigation Reform Act of 1995,
which involve risks and uncertainties. These statements relate to
future events or Onconova Therapeutics, Inc.'s future operations,
clinical development of Onconova's product candidates and
presentation of data with respect thereto, regulatory approvals,
expectations regarding the sufficiency of Onconova's cash and other
resources to fund operating expenses and capital expenditures,
Onconova's anticipated milestones and future expectations and plans
and prospects. Although Onconova believes that the expectations
reflected in such forward-looking statements are reasonable as of
the date made, expectations may prove to have been materially
different from the results expressed or implied by such
forward-looking statements. Onconova has attempted to identify
forward-looking statements by terminology including "believes,"
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "should," "approximately" or other words that
convey uncertainty of future events or outcomes. These statements
are only predictions and involve known and unknown risks,
uncertainties, and other factors, including Onconova's need for
additional financing and current plans and future needs to scale
back operations if adequate financing is not obtained, the success
and timing of Onconova's clinical trials and regulatory approval of
protocols, and those discussed under the heading "Risk Factors" in
Onconova's most recent Annual Report on Form 10-K and quarterly
reports on Form 10-Q. Any forward-looking statements contained in
this release speak only as of its date. Onconova undertakes no
obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events.
GENERAL CONTACT:
http://www.onconova.com/contact/
INVESTOR RELATIONS CONTACT:
Lisa Sher, MBS Value Partners on behalf of Onconova Therapeutics
Lisa.Sher@mbsvalue.com / (212) 750-5800
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Apr 2024 to May 2024
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From May 2023 to May 2024